Back to today’s briefing

Story perspectives

RSV Hospitalizations Drop as New Vaccines Roll Out

5/15/2025

29 3

Summary

Story summary

Infant hospitalizations from respiratory syncytial virus (RSV) plummeted in the USA during the 2024-2025 winter, thanks to a groundbreaking maternal vaccine and monoclonal antibody treatment. Meanwhile, GSK is set to introduce its RSV vaccine, Arexvy, in Korea, targeting older adults and highlighting its effectiveness in combating severe RSV-related illnesses.

1 of 1

Story summary

Infant hospitalizations from respiratory syncytial virus (RSV) plummeted in the USA during the 2024-2025 winter, thanks to a groundbreaking maternal vaccine and monoclonal antibody treatment. Meanwhile, GSK is set to introduce its RSV vaccine, Arexvy, in Korea, targeting older adults and highlighting its effectiveness in combating severe RSV-related illnesses.